TissGeneSummary for PRR19 |
Gene summary |
Basic gene information | Gene symbol | PRR19 |
Gene name | proline rich 19 | |
Synonyms | - | |
Cytomap | UCSC genome browser: 19q13.2 | |
Type of gene | protein-coding | |
RefGenes | NM_199285.2, | |
Description | proline-rich protein 19 | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000188368 | ||
HPRD : 14703 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_PRR19 | |
BioGPS: 284338 | ||
Pathway | NCI Pathway Interaction Database: PRR19 | |
KEGG: PRR19 | ||
REACTOME: PRR19 | ||
Pathway Commons: PRR19 | ||
Context | iHOP: PRR19 | |
ligand binding site mutation search in PubMed: PRR19 | ||
UCL Cancer Institute: PRR19 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of PRR19 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for PRR19 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
LUSC | -0.666733723 | -2.734112155 | 2.067378431 | 3.48E-26 | 8.81E-25 |
LUAD | -0.978902148 | -2.741386631 | 1.762484483 | 3.94E-20 | 8.11E-19 |
STAD | -0.795831027 | -2.412499777 | 1.61666875 | 3.10E-07 | 6.56E-06 |
BRCA | -0.230810194 | -2.03339879 | 1.802588596 | 2.09E-34 | 3.83E-33 |
COAD | -0.971797373 | -2.574693527 | 1.602896154 | 1.05E-09 | 1.18E-08 |
LIHC | -1.363525527 | -2.862017527 | 1.498492 | 2.04E-06 | 1.02E-05 |
ESCA | -0.920743527 | -2.6817708 | 1.761027273 | 0.00342 | 0.031045224 |
BLCA | -0.304190896 | -2.046790896 | 1.7426 | 7.02E-06 | 0.00014456 |
Top |
TissGene-miRNA for PRR19 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for PRR19 |
TissGeneSNV for PRR19 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.L95V | STAD | 1 |
p.R50W | LUAD | 1 |
p.D44N | STAD | 1 |
p.P118T | STAD | 1 |
p.R29C | PRAD | 1 |
p.P39S | STAD | 1 |
p.R163G | STAD | 1 |
p.Q9H | HNSC | 1 |
p.P100H | MESO | 1 |
p.G5* | HNSC | 1 |
p.F161L | LIHC | 1 |
p.R163Q | READ | 1 |
p.R50L | THCA | 1 |
p.P118A | HNSC | 1 |
p.E226D | CESC | 1 |
p.Q12E | LUSC | 1 |
p.R22C | STAD | 1 |
p.P110Q | SKCM | 1 |
p.P219T | UCEC | 1 |
p.E80K | SKCM | 1 |
p.R119W | UVM | 1 |
p.P118S | LGG | 1 |
p.P306L | STAD | 1 |
p.Q9L | LUAD | 1 |
p.P306S | SKCM | 1 |
p.E72K | HNSC | 1 |
p.R193W | STAD | 1 |
p.P103L | STAD | 1 |
p.A117T | STAD | 1 |
p.G302R | LUAD | 1 |
p.R19C | SKCM | 1 |
p.T57I | UCEC | 1 |
p.P45S | SKCM | 1 |
p.S218I | COAD | 1 |
Top |
TissGeneCNV for PRR19 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for PRR19 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Chimerdb3.0 | FusionScan | BRCA | TCGA-BH-A0H0-01A | PRR19-PPP1R37 | 5'UTR-CDS | chr19:42806655 | chr19:45641771 |
TCGAfusionPortal | PRADA | BRCA | TCGA-BH-A0H0-01A | PRR19-LRRC68 | 5UTR-CDS | Chr19:42806655 | Chr19:45641772 |
Top |
TissGeneNet for PRR19 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for PRR19 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for PRR19 |
TissGeneDrug for PRR19 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for PRR19 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |